This targeting group is being used in the development of a range of RNAi drugs including compound 29 for the treatment of alpha-1 antitrypsin (AAT) liver disease.115 The RNAi investigational therapeutic ARO-APOC3,116 targeting apolipoprotein C-III, is in stage three clinical trials. This evidence concerns the gene APOC3 and liver disorder.